Ambrilia Biopharma, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ambrilia Biopharma, Inc.
Digital Health Roundup: Brain Talk On Seizures, Alzheimer's, Stress, Anxiety; Medtronic's OR Report; Health Care AI; UK Guidances
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights AI discussions at the HLTH Europe conference and an interview with Motif Neurotech's CEO Jacob Robinson. Elizabeth Orr discusses DeepWell DTx's newly launched VR game for treating stress-related hypertension and anxiety. Natasha Barrow provides an overview of Digital Mental Health Technologies regulation in the UK and Brian Bossetta reports ‘the good and bad’ from Medtronic's report on digital technologies' use in the operating room.
Deal Watch: AbbVie Offloads Three Cystic Fibrosis Candidates To Sionna
Plus deals involving Abeona/Beacon, TuHura/Kintara, Crosswalk/Codexis, Lantheus/Life Molecular Imaging as well as tech transfer agreements and small deals involving Pfizer, Sanofi and Ipsen.
CordenPharma Will Scale Up To Address GLP-1 Shortage
The Swiss contractor said it will invest about $981m to increase manufacturing capacity for GLP-1 peptides in the US and EU, to fulfill API contracts worth more than $3bn.
Poland’s Quiet Pivot From Generics To Innovative Treatments
Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
- Antisense, Oligonucleotides
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice